RxDoctor Payments Data

Erasmo Passaro, MD

Neurology · St Petersburg, FLNPI 1972599439

Payments from drug & device makers

$293,524in general payments, 2019–2025

Across 591 payments — averaging $496.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • SK Life Science, Inc.$116K
  • UCB, Inc.$114K
  • Eisai Inc.$20K
  • Neurelis, Inc.$19K
  • Sunovion Pharmaceuticals Inc.$11K
  • Greenwich Biosciences, Inc.$9K
  • plus $4K from 18 others

What the payments were for

  • Consulting fees$15,9205%
  • Speaking & faculty fees$246,75584%
  • Travel & lodging$17,2056%
  • Food & beverage$13,5845%
  • Education$600%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$293,524 in reported general payments places this provider in the 85th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$420,117
Medicare patients
496
Services billed
3,055

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XcopriCenobamate188$305,525
BriviactBrivaracetam115$181,474
EpidiolexCannabidiol (Cbd)28$151,161
UbrelvyUbrogepant66$81,304
AptiomEslicarbazepine Acetate29$71,884
QuliptaAtogepant49$60,706
ValtocoDiazepam24$50,029
Lacosamide148$30,973
FycompaPerampanel18$23,788
TrileptalOxcarbazepine18$23,372
Aimovig AutoinjectorErenumab-Aooe27$22,495
NayzilamMidazolam14$19,980
Nurtec OdtRimegepant Sulfate13$19,253
Levetiracetam390$18,100
Emgality PenGalcanezumab-Gnlm18$12,286

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SK Life Science, Inc.Xcopri$116,087$305,525188 claims
UCB, Inc.Briviact, Nayzilam$114,116$201,454129 claims
AbbVieUbrelvy, Qulipta$1,006$142,010115 claims
Sunovion Pharmaceuticals Inc.Aptiom$11,367$71,88429 claims
Neurelis, Inc.Valtoco$19,127$50,02924 claims
Eisai Inc.Fycompa$20,083$23,78818 claims
PfizerNurtec Odt$21$19,25313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,434 neurology providers in Florida.

Other neurology in St Petersburg

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →